Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve Gastrectomy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Perineural ondansetron, Intravenous ondansetron.
- Who it may be relevant to
- Registry conditions: Ondansetron, Laparoscopic, Gastrectomy. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Intravenous Versus Perineural Ondansetron as an Adjuvant in Autonomic Neural Blockade for Laparoscopic Sleeve Gastrectomy: A Two-Center, Randomized, Double-Blind, Non-inferiority Trial
Overview
This prospective randomized non-inferiority study will be conducted to compare the analgesic anti-emetic effects of intravenous ondansetron versus perineural ondansetron in patients undergoing laparoscopic sleeve gastrectomy.
Detailed description
Obesity and its associated disorders have significant implications for health, resulting in heightened productivity loss and reduced life expectancy while also negatively impacting the quality of life of patients. Surgical intervention is the most effective way to achieve sustainable weight loss in patients with obesity and to alleviate the associated comorbidities. Despite the current availability of minimally invasive bariatric surgical treatments, postoperative pain remains a significant issue. Vagal and sympathetic afferent signals originating from the gastrointestinal system stimulate the vomiting center, causing nausea and vomiting. Paragastric autonomic neural blockade (PANB) is a new method performed by injecting local anesthetic material into three to four separate points along the border between the lesser omentum and the stomach (from the esophagogastric junction to the distal antrum), the hepatoduodenal ligament, and the area covering the left gastric artery. This procedure aims to prevent visceral pain and symptoms of nausea and vomiting. Ondansetron is a serotonin receptor (5-HT3) antagonist used commonly to manage postoperative nausea and vomiting (PONV) through intravenous (IV) injection. It also has a local anesthetic effect and many studies used it as adjuvant in various regional anesthetic techniques. In this study, investigators will compare the combined antiemetic analgesic effects of IV and perineural (adjuvant to the local anesthetic bupivacaine in PANB) ondansetron. The investigators hypothesized that perineural administration of ondansetron will be non-inferior to the IV route regarding prophylaxis against PONV, and will provide superior postoperative analgesic effects by its local anesthetic enhancing action.
Interventions
- Drug Perineural ondansetron
Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml (4 mg) ondansetron. At the same time, 15 ml saline will be injected slowly IV over 15 minutes. - Drug Intravenous ondansetron
Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml saline. At the same time, 4 mg (2 ml) ondansetron mixed with 13 ml saline (total 15 ml) will be slowly injected IV over 15 minutes.
Primary outcome measures
- Incidence of vomiting in the early 8 hours after surgery. [Time frame: 8 hours after surgery.]
- Degree of postoperative pain at 1 hour after surgery as measured by the numerical rating scale pain score. [Time frame: 1 hour after surgery.]
Secondary outcome measures (6)
- Incidence of postoperative nausea and vomiting at 1 h, 8 h, and at 24 hours after surgery. [Time frame: 24 hours after surgery.]
- Number of rescue anti-emetic doses in the first postoperative day. [Time frame: 24 hours after surgery.]
- Postoperative pain scores at 4 h, 8 h, and 24 hour after surgery. [Time frame: 24 hours after surgery.]
- Time to first rescue opioid analgesic. [Time frame: 24 hours after surgery.]
- Total opioid dose in the first day after surgery. [Time frame: 24 hours after surgery.]
- Patient satisfaction [Time frame: 24 hours after surgery.]
Eligibility criteria
Inclusion criteria
- Patients of either sex
- American Society Anesthesiologists physical (ASA) status II-III
- age between 18-65 years old
- Body mass index (BMI) >35 kg/m2 with comorbidity or > 40 kg/m2 -- undergoing laparoscopic sleeve gastrectomy with intraoperative surgeon performed laparoscopic paragastric autonomic neural blockade..
Exclusion criteria
- Allergy to experimental drugs.
- Known to have long QT, previous history of postoperative nausea and vomiting
- Abuse of alcohol, analgesia, or sedative antidepressant drugs
- Chronic pain disorders
- History of previous upper gastrointestinal system surgery, those with surgery-related complications during or after surgery.
- Liver or kidney failure
- Performance of concomitant procedures in addition to laparoscopic sleeve gastrectomy
- Anesthetic complications that may alter the postoperative management protocol.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Prevention
Study locations
Egypt · 1 center
- Tanta University Hospitals — Tanta
Identifiers
NCT: NCT06810882 · 36264PR1032/1/25